Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 22
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Ogunjimi, Benson Willem, Lander Beutels, Philippe and Hens, Niel 2015. Integrating between-host transmission and within-host immunity to analyze the impact of varicella vaccination on zoster. eLife, Vol. 4,

    Luyten, Jeroen Ogunjimi, Benson and Beutels, Philippe 2014. Varicella-zoster virus vaccination under the exogenous boosting hypothesis: Two ethical perspectives. Vaccine, Vol. 32, Issue. 52, p. 7175.

    Amirthalingam, Gayatri and Ramsay, Mary 2016. Should the UK introduce a universal childhood varicella vaccination programme?. Archives of Disease in Childhood, Vol. 101, Issue. 1, p. 2.

    Kawai, K. Gebremeskel, B. G. and Acosta, C. J. 2014. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open, Vol. 4, Issue. 6, p. e004833.

    Ogunjimi, Benson Theeten, Heidi Hens, Niel and Beutels, Philippe 2014. Serology indicates cytomegalovirus infection is associated with varicella-zoster virus reactivation. Journal of Medical Virology, Vol. 86, Issue. 5, p. 812.

    Helmuth, Ida Glode Poulsen, Anja Suppli, Camilla Hiul and Mølbak, Kåre 2015. Varicella in Europe—A review of the epidemiology and experience with vaccination. Vaccine, Vol. 33, Issue. 21, p. 2406.

    Panatto, Donatella Bragazzi, Nicola Luigi Rizzitelli, Emanuela Bonanni, Paolo Boccalini, Sara Icardi, Giancarlo Gasparini, Roberto and Amicizia, Daniela 2015. Evaluation of the economic burden of Herpes Zoster (HZ) infection. Human Vaccines & Immunotherapeutics, Vol. 11, Issue. 1, p. 245.

    Morant-Talamante, Nuria Diez-Domingo, Javier Martínez-Úbeda, Sergio Puig-Barberá, Joan Alemán-Sánchez, Sara and Pérez-Breva, Lina 2013. Herpes zoster surveillance using electronic databases in the Valencian Community (Spain). BMC Infectious Diseases, Vol. 13, Issue. 1,

    Esteban-Vasallo, M.D. Gil-Prieto, R. Domínguez-Berjón, M.F. Astray-Mochales, J. and Gil de Miguel, A. 2014. Temporal trends in incidence rates of herpes zoster among patients treated in primary care centers in Madrid (Spain), 2005–2012. Journal of Infection, Vol. 68, Issue. 4, p. 378.

    Gater, Adam Uhart, Mathieu McCool, Rachael and Préaud, Emmanuelle 2015. The humanistic, economic and societal burden of Herpes Zoster in Europe: a critical review. BMC Public Health, Vol. 15, Issue. 1, p. 193.

    Herdman, Michael Cole, Amanda Hoyle, Christopher K. Coles, Victoria Carroll, Stuart and Devlin, Nancy 2016. Sources and Characteristics of Utility Weights for Economic Evaluation of Pediatric Vaccines: A Systematic Review. Value in Health, Vol. 19, Issue. 2, p. 255.

    Betta, Monica Laurino, Marco Pugliese, Andrea Guzzetta, Giorgio Landi, Alberto and Manfredi, Piero 2016. Perspectives on optimal control of varicella and herpes zoster by mass routine varicella vaccination. Proceedings of the Royal Society B: Biological Sciences, Vol. 283, Issue. 1826, p. 20160054.

    Schmidt, Sigrun A. J. Kahlert, Johnny Vestergaard, Mogens Schønheyder, Henrik C. and Sørensen, Henrik T. 2016. Hospital-based herpes zoster diagnoses in Denmark: rate, patient characteristics, and all-cause mortality. BMC Infectious Diseases, Vol. 16, Issue. 1,

    Chui, Ka-Sing Wu, Hiu-Lok and You, Joyce H. S. 2014. Cost-effectiveness analysis of varicella vaccine as post-exposure prophylaxis in Hong Kong. Scandinavian Journal of Infectious Diseases, Vol. 46, Issue. 1, p. 27.

    Chen, Qiping Hsu, Tun-Ying Chan, Roy Kawai, Kosuke Acosta, Camilo J. Walia, Anuj and Pan, Jiun Yit 2015. Clinical and economic burden of herpes zoster and postherpetic neuralgia in patients from the National Skin Centre, Singapore. Dermatologica Sinica, Vol. 33, Issue. 4, p. 201.

    Bilcke, Joke Jan van Hoek, Albert and Beutels, Philippe 2013. Childhood varicella-zoster virus vaccination in Belgium: Cost-effective only in the long run or without exogenous boosting?. Human Vaccines & Immunotherapeutics, Vol. 9, Issue. 4, p. 812.

    Lalwani, Sanjay Chatterjee, Sukanta Balasubramanian, Sundaram Bavdekar, Ashish Mehta, Shailesh Datta, Sanjoy Povey, Michael and Henry, Ouzama 2015. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial. BMJ Open, Vol. 5, Issue. 9, p. e007202.

    Ogunjimi, Benson Buntinx, Frank Bartholomeeusen, Stephaan Terpstra, Ita De haes, Inke Willem, Lander Elli, Steven Bilcke, Joke Van Damme, Pierre Coenen, Samuel and Beutels, Philippe 2015. Herpes zoster is associated with herpes simplex and other infections in under 60 year-olds. Journal of Infection, Vol. 70, Issue. 2, p. 171.

    Hobbelen, Peter H.F. Stowe, Julia Amirthalingam, Gayatri Miller, Liz and van Hoek, Albert-Jan 2016. The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013. Journal of Infection, Vol. 73, Issue. 3, p. 241.

    Bella, Antonino Trucchi, Cecilia Gabutti, Giovanni and Cristina Rota, Maria 2015. Burden of varicella in Italy, 2001–2010: analysis of data from multiple sources and assessment of universal vaccination impact in three pilot regions. Journal of Medical Microbiology, Vol. 64, Issue. 11, p. 1387.


The health and economic burden of chickenpox and herpes zoster in Belgium

  • J. BILCKE (a1), B. OGUNJIMI (a1) (a2), C. MARAIS (a1), F. DE SMET (a3) (a4), M. CALLENS (a3), K. CALLAERT (a5), E. VAN KERSCHAVER (a6), J. RAMET (a2), P. VAN DAMME (a1) and P. BEUTELS (a1)
  • DOI:
  • Published online: 10 January 2012

Varicella-zoster virus causes chickenpox (CP) and after reactivation herpes zoster (HZ). Vaccines are available against both diseases warranting an assessment of the pre-vaccination burden of disease. We collected data from relevant Belgian databases and performed five surveys of CP and HZ patients. The rates at which a general practitioner is visited at least once for CP and HZ are 346 and 378/100 000 person-years, respectively. The average CP and HZ hospitalization rates are 5·3 and 14·2/100 000 person-years respectively. The direct medical cost for HZ is about twice as large as the direct medical cost for CP. The quality-adjusted life years lost for ambulatory CP patients consulting a physician is more than double that of those not consulting a physician (0·010 vs. 0·004). In conclusion, both diseases cause a substantial burden in Belgium.

Corresponding author
*Author for correspondence: Dr J. Bilcke, Center for Health Economic Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (Vaxinfectio), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium. (Email:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

3.L Annemans , Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. Journal of Medical Economics 2010; 13: 537551.

4.AM Arvin , CM Koropchak , AE Wittek . Immunological evidence of reinfection with varicella-zoster virus. Journal of Infectious Diseases 1983; 148: 200205.

5.B Ogunjimi , Exploring the impact of exposure to primary varicella in children on varicella-zoster virus immunity of parents. Viral Immunology 2011; 24: 151157.

6.MTM Vossen , Development of virus-specific CD4(+) T cells on reexposure to varicella-zoster virus. Journal of Infectious Diseases 2004; 190: 7282.

7.AO Jumaan , Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992–2002. Journal of Infectious Diseases 2005; 191: 20022007.

8.J Leung , Herpes zoster incidence among insured persons in the United States, 1993–2006: evaluation of impact of varicella vaccination. Clinical Infectious Diseases 2011; 52: 332340.

10.WK Yih , The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998–2003. BMC Public Health 2005; 5: 68.

11.M Brisson , Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002; 20: 25002507.

12.AA Gershon , The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox. Journal of Infectious Diseases 1996; 173: 450453.

13.SL Thomas , JG Wheeler , AJ Hall . Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002; 360: 678682.

15.AJ van Hoek , Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England. Vaccine 2011; 29: 24112420.

16.M Brisson , WJ Edmunds . Varicella vaccination in England and Wales: cost-utility analysis. Archives of Disease in Childhood 2003; 88: 862869.

20.MN Oxman , A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine 2005; 352: 22712284.

21.PM Coplan , Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. Journal of Pain 2004; 5: 344356.

22.M Brisson , WJ Edmunds . Epidemiology of varicella-zoster virus in England and Wales. Journal of Medical Virology 2003; 70 (Suppl. 1): S9–14.

23.P Coplan , Incidence and hospitalization rates of varicella and herpes zoster before varicella vaccine introduction: a baseline assessment of the shifting epidemiology of varicella disease. Pediatric Infectious Disease Journal 2001; 20: 641645.

25.KJ Smith , MS Roberts . Cost effectiveness of vaccination strategies in adults without a history of chickenpox. American Journal of Medicine 2000; 108: 723729.

26.DL Sackett , GW Torrance . The utility of different health states as perceived by the general public. Journal of Chronic Diseases 1978; 31: 697704.

27.P Merrett , Strategies to prevent varicella among newly arrived adult immigrants and refugees: A cost-effectiveness analysis. Clinical Infectious Diseases 2007; 44: 10401048.

29.FT Scott , The burden of herpes zoster: a prospective population based study. Vaccine 2006; 24: 13081314.

30.W Opstelten , Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: prospective prognostic study. Pain 2007; 132 (Suppl. 1): S52–9.

31.M Drolet , The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. Canadian Medical Association Journal 2010; 182: 17311736.

32.BP Yawn , Herpes zoster recurrences more frequent than previously reported. Mayo Clinic Proceedings 2011; 86: 8893.

33.DW Wareham , J Breuer . Herpes zoster. British Medical Journal 2007; 334: 12111215.

35.RP Insinga , RF IItzler , JM Pellissier . Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans. Pharmacoeconomics 2007; 25: 155169.

36.RR White , Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. Pharmacoeconomics 2009; 27: 781792.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *